In that trial, 2272 patients with completelyresected Stage IB-II or IIIA NSCLC (with and without adjuvant chemotherapy)with positive MAGE-A3 expression were randomly assigned (2:1) to receiveeither MAGE-A3 immunotherapy or placebo. Here, MAGEA3 is linked to non-small cell lung carcinoma.